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Abstract
Reverse transcription is the central defining feature of HIV-1 replication. We previously
reported that the cellular eukaryotic elongation factor 1 (eEF1) complex associates with the
HIV-1 reverse transcription complex (RTC) and the association is important for late steps of
reverse transcription. Here we show that association between the eEF1 and RTC complexes
occurs by a strong and direct interaction between the subunit eEF1A and reverse transcrip-
tase (RT). Using biolayer interferometry and co-immunoprecipitation (co-IP) assays, we
show that association between the eEF1 and RTC complexes occurs by a strong (KD ~3–4
nM) and direct interaction between eEF1A and reverse transcriptase (RT). Biolayer interfer-
ometry analysis of cell lysates with titrated levels of eEF1A indicates it is a predominant cellu-
lar RT binding protein. Both the RT thumb and connection domains are required for
interaction with eEF1A. A single amino acid mutation, W252A, within the thumb domain
impaired co-IP between eEF1A and RT, and also significantly reduced the efficiency of late
reverse transcription and virus replication when incorporated into infectious HIV-1. Molecular
modeling analysis indicated that interaction betweenW252 and L303 are important for RT
structure, and their mutation to alanine did not impair heterodimerisation, but negatively
impacted interaction with eEF1A. Didemnin B, which specifically binds eEF1A, potently
inhibited HIV-1 reverse transcription by greater than 2 logs at subnanomolar concentrations,
especially affecting reverse transcription late DNA synthesis. Analysis showed reduced lev-
els of RTCs from HIV-1-infected HEK293T treated with didemnin B compared to untreated
cells. Interestingly, HIV-1 with a W252A RTmutation was resistant to didemnin B negative
effects showing that didemnin B affects HIV-1 by targeting the RT-eEF1A interaction. The
combined evidence indicates a direct interaction between eEF1A and RT is crucial for HIV
reverse transcription and replication, and the RT-eEF1A interaction is a potential drug target.
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Author Summary
After infecting a target cell, HIV-1 like all retroviruses converts the viral single strand
RNA genome into double strand DNA by the process called reverse transcription. Host
proteins are known to be important for reverse transcription yet a direct role for any host
protein has not been demonstrated. In this paper, we show that a eukaryotic translation
elongation factor (eEF1A), an abundant cellular protein, directly and strongly binds to the
viral enzyme reverse transcriptase (RT). The biological relevance of the association is sup-
ported by mutational analysis of RT and by treating cells with the small molecule didem-
nin B that specifically binds eEF1A. Mutation of RT or treatment of cells with didemnin B
resulted in significantly decreased efficiency of reverse transcription. Didemnin B treat-
ment of cells disrupted HIV-1’s ability to maintain the viral machinery necessary for
reverse transcription. However, an HIV-1 mutant, which does not interact with eEF1A,
was resistant to didemnin B negative effects on early viral replication, showing that didem-
nin B affects HIV-1 by targeting the RT-eEF1A interaction. Altogether, this study demon-
strates that eEF1A is an integral component of the viral reverse transcription complex and
that the RT-eEF1A interaction is a possible new drug target to inhibit HIV-1 replication.
Introduction
To convert the viral genomic RNA into double stranded DNA, HIV-1 forms a prototypical
ribonucleoprotein complex on the viral genomic RNA called the reverse transcription complex
(RTC) [1]. It includes the viral enzymes reverse transcriptase (RT) and integrase (IN), as well
as other viral proteins including capsid (CA), matrix (MA), viral protein R (Vpr), and viral
infectivity factor (Vif). The complex assembles on the 5’ untranslated region (UTR) of HIV-1
genomic RNA and requires tRNALys3, which anneals to a viral primer binding site sequence so
that DNA synthesis can initiate. Reverse transcription can also be regulated by viral proteins
such as Tat [2–5]. HIV-1 reverse transcription begins shortly after the viral core enters the cell
cytoplasm, when nucleotides become available to make a short single strand of DNA referred
to as minus strand strong stop DNA (sssDNA or early DNA). Studies show that completion of
in vitro reverse transcription can be greatly enhanced by the addition of cell lysate, indicating
that one or more cellular activities are required to form RTC and enable its full function [6–8].
Recently, two subunits of the eukaryotic elongation factor 1 (eEF1) complex, eEF1A1 (here-
after referred to as eEF1A) and eEF1G, were found to associate with RT and IN [9]. The cellular
eEF1 complex is composed of several subunit proteins and co-factors [10]. These include
eEF1A and the eEF1B complex (composed of eEF1G, eEF1B, eEF1D and valyl-tRNA synthe-
tase). During protein synthesis, eEF1A binds to and delivers aminoacetylated transfer RNAs
(aa-tRNAs) to the elongating ribosome. In the study by Warren et al. [9], only cell lysate frac-
tions containing the eEF1 complex strongly stimulated late stages of reverse transcription. In
HIV-1 infected cells, eEF1 components eEF1A and eEF1G were shown to co-purify with the
RTC and depletion of either by siRNA knock down resulted in instability of the RTC in cells,
which reduces synthesis of late DNA but not early DNA products of reverse transcription [9].
These outcomes were consistent with the previous observation that cell lysate stimulated late
steps of reverse transcription [6,11]. Exactly how eEF1 subunits interact with the RTC is
unknown, and therefore the focus of this study.
This study aimed to characterize the association between eEF1 and HIV-1 RTC complexes,
and its roles in virus reverse transcription and replication. We found that a specific, strong and
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direct binding between eEF1A and RT is a dominant interaction that can account for the asso-
ciation between eEF1 and RTC complexes.
Results
eEF1A exhibits strong and direct binding to HIV-1 RT
To further characterize the association between eEF1 complex and the RTC, we used biolayer
interferometry (BLI) assays to determine if a specific subunit of the eEF1 complex could
directly bind to RT or IN. The BLI method uses the interference pattern of white light reflected
from two surfaces on a biosensor probe: a layer of immobilized protein of interest and an inter-
nal reference layer. Any change in the number of molecules bound to the biosensor tip due to
protein-protein interaction causes a shift in the interference pattern that can be measured.
Purified RT p66/p51 heterodimer was biotinylated and immobilized on a streptavidin-coated
Octet-Red system biosensor. The interaction of RT p66/51 with individual subunits of the
eEF1 complex, including eEF1A, eEF1B, eEF1G and eEF1D, was assessed using solutions con-
taining 60 nM of individual recombinant eEF1 subunits. Only eEF1A demonstrated strong
binding with RT, while weak binding was observed between eEF1B and eEF1G with RT and no
interaction was detected between eEF1D and RT under the conditions tested (Fig 1A). A simi-
lar experiment was performed using a biosensor labeled with HIV-1 IN and the same eEF1 sub-
units. All subunits of eEF1 showed very weak or negligible interaction with IN (Fig 1B). We
performed a reciprocal experiment in which biosensors were labeled with individual eEF1 sub-
units and incubated with solutions containing RT heterodimer at 90, 30 and 10 nM. A concen-
tration-dependent binding of eEF1A with RT was detected along with weak binding of eEF1B
(S1 Fig). These results indicate that an association of the HIV-1 RTC with the eEF1complex, as
identified in our early study [9], is occurring via the direct binding between RT and eEF1A
components of the two complexes, respectively.
Next we compared the interaction of individual RT subunits or the heterodimer with eEF1A
using eEF1A-labeled biosensors. HIV-1 Gag protein, a previously reported eEF1A binding pro-
tein [12] was included as a control. The BLI assays showed a concentration-dependent interac-
tion between the proteins tested (S2 Fig). The goodness of curve fit was indicated by low
apparent χ2 of 1.07 to 2.12, where below 10 is considered acceptable [13]. The combined results
revealed a binding hierarchy where RTp66 RTp66/p51> RTp51> Gag. The KD of eEF1A
with RT subunits ranged from 3–4 nM for RTp66, RTp66/p51 and RTp51 and 21 nM for Gag
under the conditions tested, indicating that each RT subunit can form a stable protein complex
with eEF1A (Table 1).
The binding of RT subunits and Gag with eEF1A was confirmed using co-immunoprecipi-
tation (co-IP) experiments. RT subunits and Gag, each with a C-terminal FLAG-tag, were
expressed in HEK293T cells individually or in combination (Fig 1C). Cell lysates prepared 24 h
post-transfection were incubated with protein G-conjugated agarose beads bound with a rabbit
anti-eEF1A antibody. Western blot analysis of immunoprecipitated proteins indicated that RT
subunits associated with eEF1A better than Gag (Fig 1C). A reciprocal IP experiment showed
that RTp51 could co-IP eEF1A (S3 Fig). Our combined data indicates that eEF1A interacts
with individual RT subunits or the RT heterodimer both directly and strongly.
As eEF1A is an abundant cellular protein that tightly binds HIV-1 RT, it is possible that
eEF1A is a dominant cellular RT binding protein. To examine this possibility, eEF1A levels
were downregulated using previously described siRNAs [9] and the association of total cellular
protein with an RTp66/p51 biosensor was examined by BLI. In BLI only molecules binding to
or dissociating from the biosensor can shift the interference pattern. Hence crude cell lysate
can be used in BLI assays to investigate protein-protein interaction [14]. Protein concentration
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Fig 1. eEF1A binds directly and tightly to HIV-1 RT in vitro. (A) Biolayer interferometry assays (BLI) of a
biotinylated HIV RTp66/p51-loaded biosensor with 60 nM of purified eEF1A, eEF1B, eEF1D, eEF1G or BSA
as analytes. (B) BLI assays using a biotinylated HIV-1 IN-loaded biosensor as described in (A). (C) Co-IP of
RT with eEF1A. HEK 293T cells were transfected with plasmids to express FLAG-tagged RTp66, RTp51,
both RTp51 and RTp66, or Gag. Expression of the proteins in cell lysates was confirmed by western blot
using anti-FLAG antibody (upper panel). The cell lysate was used for co-IP analysis with a rabbit anti-eEF1A
capture antibody. Capture of RT subunits and Gag was examined by western blot with an anti-FLAG antibody
(second panel). Western blot with a mouse anti-eEF1A antibody was used to confirm eEF1A capture (third
panel). Nonspecific binding to the beads was excluded by IP using an anti-rabbit IgG capture antibody
followed by western blot using an anti-FLAG antibody (lower panel). (D) HEK293T cells were treated with two
eEF1A siRNAs, one control siRNA or no siRNA for 48 h before preparing a cell lysate. The levels of eEF1A
(upper panel) and β tubulin (lower panel) in the cell lysate were determined by western blot. Densitometry
analysis of the western blot image was used to calculate the relative levels of eEF1A in each siRNA-treated
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of siRNA-treated and control lysates was carefully monitored using a bioanalyzer and con-
firmed by western blot using an anti-β tubulin antibody (Fig 1D, bottom panel). The eEF1A
siRNA1 and siRNA2 treated cell lysates had reduced eEF1A levels of>80% and>40%, respec-
tively, and showed reduced association with the RT biosensor compared to lysates from control
siRNA treated cells and untreated cell lysates (Fig 1E), which correlated to the levels of eEF1A
present in each cell lysate (Fig 1D, top panel). Addition of purified MYC/DDK-tagged eEF1A
to an eEF1A-depleted cell lysate restored the BLI interference response (Fig 1F) showing that
the response curves reflected eEF1A levels in the cell lysates. The results provide evidence that
eEF1A is a predominant RT binding protein in cells.
The RT thumb and connection domains are important for interaction with
eEF1A
To determine the region of RT that is important for interaction with eEF1A, a series of C-ter-
minal deletions of RT domains were made, each tagged with a C-terminal V5 epitope (Fig 2A).
The wild type or mutated RT expression plasmids were transfected into HEK293T cells and
western blots were performed to show that all RT proteins were expressed (Fig 2C, top panel).
Immunoprecipitation of eEF1A showed reduced co-IP of RT when the connection domain was
deleted, and no co-IP was detected when both the thumb and connection domains were deleted
(Fig 2C, middle panel). The results indicate that the RT thumb and connection domains are
required for interaction with eEF1A. Another series of N-terminal and internal deletions in RT
were made to further investigate the role played by the thumb and connection domains in the
eEF1A interaction (Fig 2B). An expression plasmid containing only the thumb and connection
domains (RT-ΔF+P) expressed protein at low levels (Fig 2D, top panel) but was strongly co-
immunoprecipitated by eEF1A (Fig 2D, middle panel), confirming that the thumb and connec-
tion domains are important for binding to eEF1A. The RT thumb domain (residues 244–323)
contains 3 alpha helices: helix H (residue 255–268), helix I (residues 278–286) and helix J (resi-
dues 298–311). Three RT constructs having internal deletions in the thumb domain were made
to see if the entire thumb domain or a specific region was required for interaction with eEF1A.
Deletion of the whole thumb domain, deletion of helix H alone and deletion of helices I and J
combined, each resulted in a reduced co-IP of RT with eEF1A (Fig 2D). The combined data
sample compared to the untreated control (E) Sensorgrams of association and dissociation of cell lysates
containing various levels of eEF1A to RTp66-biosensors. (F) Addition of purified MYC/DDK-eEF1A1 protein
to a cell lysate where eEF1A was strongly reduced by siRNA treatment restored a sensograms profile
indicative of strong RT interaction. All experiments were performed at least three times and representative
results are shown.
doi:10.1371/journal.ppat.1005289.g001
Table 1. Association and dissociation parameters of eEF1Awith RT subunits, RT heterodimer and Gag in BLI assays.
Ka (1/MS) (1) Kd (1/second) (2) KD (nM)
(3) χ2 (4)
RT p51 4.48 ± 2.31×104 1.85 ± 3.67×10−4 4.13 ± 2.32 1.25 ± 0.46
RT p66 6.95 ± 4.68×104 2.22 ± 1.05×10−4 3.19 ± 1.08 2.12 ± 1.08
RT p51/66 5.52 ± 3.16×104 2.07 ± 1.72×10−4 3.75 ± 1.04 1.86 ± 0.78
Gag 8.75 ± 4.43×104 1.88 ± 2.56×10−3 21.49 ± 11.08 1.07 ± 0.29
(1) association rate constants (ka): The rate of complex formed per second in a 1 molar solution of each component.
(2) dissociation rate constant (kd): Stability of the complex, i.e. the fraction of complexes decays per second.
(3) afﬁnity constant (KD): KD = kd/ka.
(4) chi-square test
doi:10.1371/journal.ppat.1005289.t001
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Fig 2. The RT thumb and connection domains are required for RT-eEF1A interaction. (A andB) Schematic diagrams representing V5-tagged RT
truncation and deletion mutants, indicating important RT domains. (C andD) Lysates from cells transiently expressing each wild type or mutant RT subunit,
as indicated (top panels), were immunoprecipitated with an anti-eEF1A antibody and analyzed by western blot with an anti-V5 antibody (middle panels).
Nonspecific binding to the beads was excluded by IP using an anti-rabbit IgG capture antibody followed by western blot using an anti-V5 antibody (bottom
panels). (E) Lysates from transiently transfected cells expressing RTp51-V5 having non-overlapping mutations consisting of 5 consecutive alanine
substitutions, (F) overlapping double alanine substitutions), or (G) single alanine substitutions (top panels) were visualized by western blot. Co-IP of RTp51
and RTp66 proteins using an anti-eEF1A antibody were visualized by western blot with an anti-V5 antibody (middle panels). Nonspecific binding to the beads
was excluded by IP using an anti-rabbit IgG capture antibody followed by western blot using an anti-V5 antibody (bottom panels). All experiments were
performed at least three times and representative results are shown.
doi:10.1371/journal.ppat.1005289.g002
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show that the connection and thumb domains of RT are required for interaction with eEF1A
where multiple binding determinants in these domains mediate a stable protein interaction
with eEF1A.
Alanine substitution mutagenesis reveals residues in the thumb domain
critical for RT interaction with eEF1A
As deletion of either N- or C-terminal regions of the RT thumb domain impaired the RT-
eEF1A interaction, we used alanine substitution mutations to screen positions in the thumb
domain that could mediate the RT-eEF1A interaction. We mutated the RTp51-V5 expression
plasmid to make 15 non-overlapping substitutions consisting of 5 consecutive alanine residues
that covered the thumb domain of RT. The RT expression plasmids were individually trans-
fected into HEK293T cells and western blots of cell lysates prepared from the cells showed that
each RT protein was made (Fig 2E, top panels). Co-IP analysis using an anti-eEF1A antibody
identified mutations in two regions of the thumb domain, residues 249–253 and 294–313, that
downregulated association of RT p51 with eEF1A (Fig 2E, middle panels). The mutation of res-
idues 249–253 was investigated further by introducing overlapping double alanine mutations
to make four new mutant RTp51-V5 expression plasmids: 249-250A, 250-251A, 251-252A and
252-253A. Co-IP experiments showed that the alanine substitutions 251-252A and 252-253A
impaired interaction with eEF1A (Fig 2F), suggesting that W252 is important for the interac-
tion. Single alanine substitutions at residues W252 or T253 were further evaluated and the
W252A mutation significantly inhibited co-IP of RT with eEF1A, while the effect of the T253A
mutation was minor compared to co-IP of wild type RT (Fig 2G). The result indicates that
maintenance of W252 in RT is particularly important for its interaction with eEF1A.
TheW252A mutation is important for RT structure but does not impair
heterodimer formation
The X-ray crystal structure of the HIV-RT p66/p51 heterodimer (PDB B ID: 4G1Q, resolution
1.51 Å) [15] is shown (S4 Fig). The individual subunits that make up the heterodimer are iden-
tical in sequence, with the exception of the additional domain present in p66, absent in p51
(Fig 3A). The finger and palm structural domains in both subunits are made up from discon-
tinuous regions of sequence. Structurally, the W252A mutation is located within the loop
region that links the palm domain to the thumb domain, proximal to the first alpha-helix of
the thumb domain, but distal to the inter-subunit interface (S4 Fig). The bulky aromatic side-
chain of W252 is completely buried within the core of the protein, and supports numerous
hydrophobic interactions with spatially proximal residues, including P247 (also located within
the loop region between palm and thumb domains) and other residues in the thumb domain,
I257, L260, L295 and L303 in both subunits. These interactions are mirrored in both subunits
in this high resolution structure (Fig 3B). Given that W252 side-chain is buried in the RT core,
it is unlikely to directly facilitate interaction between RT and eEF1A.
Thermodynamic stability calculations using the empirical forcefield FoldX program show
that the mutation W252A severely destabilizes structure in both individual subunits and within
the heterodimer (ΔΔG of mutations range between ~4.7–5.3 kcal/mol) (Table 2). In contrast,
mutation T253A reveals no adverse effect on protein stability [16–18]. This is in keeping with
analysis of the lowest energy conformer of 252A (in both individual subunits and the heterodi-
mer), which shows that critical hydrophobic interactions with three of the aforementioned
interacting residues, P247, L260 and L303, are lost in the absence of the aromatic side-chain of
W252 and could render this region more “open” or flexible. The predicted reduced stability of
W252A could therefore have consequences on protein conformation that could in turn impact
The Cell Factor eEF1A Is an Important HIV RT Binding Protein
PLOS Pathogens | DOI:10.1371/journal.ppat.1005289 December 1, 2015 7 / 27
Fig 3. Point mutations in the thumb domain affect RT structure and interaction with eEF1A. (A)
Schematic diagrams representing domains of RT p66 and p51. (B) Surface representation of the p66/p51
heterodimer is shown along with a ribbon schematic representation, colored by domain with a transparency
setting to allow visualization of the buriedW252 residue and its interacting residues. The location of the W252
residue is shown; its side-chain atoms are shown as red spheres. Residues that make hydrophobic contacts
with W252 are shown colored green and labeled. The side-chain of W252 supports numerous hydrophobic
interactions with spatially proximal residues, including P247, I257, L260, L295 and L303. (C) Co-IP assays
were performed with wild type and RTmutations predicted to interact with RTW252. Mutations flanking
L295A and L303A, T296A and L301A, were included as controls. Only the L303A RTmutation reduced
interaction with eEF1A in a co-IP assay as performed in Fig 2. The experiment was performed three times
with similar results and a representative data set is shown. (D) A BLI assay using purified eEF1A immobilized
on the biosensors and purified 6ᵡHis-tagged RTp66 protein in the solution. The association of 90 nM of wild
type RT and RTmutant proteins was compared as indicated. The data is presented as a mean
value ± standard deviation from 3 independent experiments. *p<0.05.
doi:10.1371/journal.ppat.1005289.g003
The Cell Factor eEF1A Is an Important HIV RT Binding Protein
PLOS Pathogens | DOI:10.1371/journal.ppat.1005289 December 1, 2015 8 / 27
on RT:eEF1A interaction. To test this possibility further, wild type RTp51 or p51 with the sin-
gle mutations L295A, T296A, L301A, and L303A were subjected to co-IP analysis as previously
described. These residues were chosen because L295 and L303 interact with W252, and are in
the region of 294–303 where mutation significantly impairs binding to eEF1A (Fig 2C), while
neighbouring residues T296 and L301 were mutated to alanine for comparison. While the
interaction between eEF1A and L295A, T296A and L301A were comparable to wild type RT,
the L303A mutant, like W252A, interacted poorly with eEF1A (Fig 3C), which likely accounts
for the reduction in interaction of the 299-303A amino acid mutations with eEF1A. These
results suggest that a spatially proximal region, supported by W252 and L303 hydrophobic
interactions, are necessary for interaction with eEF1A. A reduced interaction of eEF1A with
RTW252A and L303A was further confirmed using BLI assay. The eEF1A biosensors were
incubated in bacterially produced 6×his recombinant wild type RTp66 at 90, 30 and 10 nM, or
mutant RTp66 W252A and L303A RT at 90 nM (Fig 3E; S5A and S5B Fig). The binding
responses of 90 nM 252A or 303A with eEF1A was substantially lower than 90 nM wild type
RT, and on par with responses measured for 10 nM of wild type RTp66. As L303A and W252A
RT mutation have similar affect on interaction with eEF1A, W252A was selected for use in fur-
ther experiments.
RT heterodimer formation requires interaction between the connection domains of RTp51
and RTp66. In order to assess the effect of the W252A mutation on RT heterodimerization, a
mammalian protein-protein interaction trap (MAPPIT) assay was undertaken [19,20] (S6 Fig).
We co-transfected various combinations of wild type and mutant RT p51 and RT p66 prey and
bait expression plasmids along with the reporter and a transfection control plasmid
pCMV-Gluc2 in HEK293T cells and compared firefly luciferase levels induced by leptin stimu-
lation (S7 Fig). The W252A and T253A mutations did not affect luciferase expression indicat-
ing that heterodimerization between R p51 and RT p66 harboring mutations were not affected.
As previously reported, L234A had a significant reduction of the signal indicating this muta-
tion negatively affect RT dimerization thus validating the system [21,22]. The results therefore
indicate that W252A imparts only a localized effect on structure stability.
TheW252A mutation regulates reverse transcription in vitro
The RTW252 residue is largely invariant among published HIV-1 sequences but to our knowl-
edge has not been investigated. Using an HIV-1NL4.3 proviral DNA plasmid, the RTW252A
mutation was introduced in pol so that infectious virus could be produced. The HIV-1 wild-
type and W252A RT mutant proviral plasmids were transfected into HEK293T cells, along
Table 2. In silico calculation of the effect of HIV-1 RT p66/p51mutations on protein stability compared
to wild type.
Mutation Stability Energy Calculation (Average ΔΔG, kcal/mol) 1
W252A (p51) 5.30
W252A (p66) 4.68
W252A (p51 in p66/p51 heterodimer 5.27
W252A (p66 in p66/p51 heterodimer) 4.71
T253A (p51) 0.37
T253A (p66) 0.62
T253A (p51 in p66/p51 heterodimer) 0.29
T253A (p66 in p66/p51 heterodimer) 0.64
1. Average of 3 calculation runs is reported.
doi:10.1371/journal.ppat.1005289.t002
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with a control plasmid pCMV-Gluc2, and cell lysates and culture supernatants were collected
at 48 h post-transfection. The expression of HIV-1 proteins in the cell lysate was examined by
western blot using an anti-HIV-1 polyclonal antibody and virus particle production was deter-
mined by p24 ELISA from the culture supernatant. The levels of Gaussia luciferase were deter-
mined and used to normalize results for transfection efficiency. The levels, patterns and ratios
of viral proteins in cell lysates were similar between the wild type and mutant (Fig 4A). Virus
particle production of the W252A RT mutant in culture supernatant was slightly reduced com-
pared to wild type virus (Fig 4B). Western blot of partially purified virions using an anti-HIV-1
polyclonal antibody or an anti-RT antibody showed similar protein staining patterns of viral
proteins and RT (Fig 4C), suggesting that an W252A RT mutation did not significantly affect
Gag-Pol steady-state levels or its cleavage by HIV-1 protease.
The thumb domain plays a role during reverse transcription to help properly position the
viral nucleic acid through interactions that involve both the primer and template strands [23],
so a W252A mutation could affect RT activity. To test this hypothesis, equal amounts of wild
type or W252A RT mutant virus, normalized to CA levels, were used in a standard in vitro RT
assay. Each virus sample was incubated in reaction mixtures containing primer, template and
nucleotides for 2 h at 37°C. The results show that a W252A RT mutation reduced the level of
RT activity by ~50% (Fig 4D). Hence a W252A RT mutation can down regulate both RT activ-
ity and the interaction between eEF1A and RT.
TheW252A RTmutation affects late steps of reverse transcription and
virus replication
The effect of a W252A RT mutation on reverse transcription efficiency was assessed in infected
cells. Jurkat cells were infected with HIV-1 normalized to one of two parameters: using an
equivalent amount of CA or an equivalent amount of total RT activity. The cells were incubated
with virus for 2 h at 4°C to enable virus attachment and then at 37°C for 4 h to initiate virus
entry and reverse transcription. The cytoplasmic nucleic acids were isolated 4 h later and levels
of viral early DNA and late DNA were measured by qPCR, and the values were normalized to
the total mitochondrial DNA present in each sample. Heat inactivated viruses were used as a
negative control. When the infections were normalized to CA, the W252A RT mutant virus
produced early viral DNA at levels slight lower than wild type virus (p> 0.05; Table 3), but the
levels of late viral DNA made by the W252A RT mutant virus was significantly reduced
(p< 0.05). The results show that the efficiency of reverse transcription, defined as the ratio of
sssDNA levels to second strand transfer DNA levels, was reduced by 2-fold in the mutant virus
compared to wild type HIV-1 (Table 3). When the amount of virus used for infection was nor-
malized to total RT activity, thereby increasing the input of W252A RT mutant virus relative to
wild type, the level of early DNAmade by the W252A RT virus was proportionally increased,
but the relative efficiency of reverse transcription remained low compared to wild type HIV-1
(Table 3). As expected, replication of the W252A RT virus was much weaker than wild type in
Jurkat cells (Fig 4E and 4F). To examine whether synthesis of late reverse transcription DNA
was more sensitive to RT activity changes rather than early reverse transcription DNA levels,
the efficiency of reverse transcription was assessed by wild type virus infection in the presence
of an RT inhibitor, nevirapine. When nevirapine was used to inhibit RT activity by ~50%, syn-
thesis of both early and late DNA products were equally affected so that the overall efficiency
of reverse transcription was unchanged (Table 3). The combined results suggest that the
W252A RT mutation affects late DNA synthesis due to changes in the RT-eEF1A interaction
rather than due to reduced RT activity per se, and this significantly reduced HIV-1 replication.
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Fig 4. AW252A RTmutation inhibits HIV-1 reverse transcription and replication. (A) Proviral plasmids transiently expressing wild type or W252A RT
mutant HIV-1 in HEK293T cells were visualized by western blot using a rabbit anit-HIV-1 antibody. Western blot samples were normalized for transfection
efficiency using a co-transfectedGaussia luciferase reporter plasmid. (B) The amount of virus present in culture supernatant was measured using a CA
ELISA. Results are normalized for transfection efficiency as determined by secretedGaussia luciferase. (C) Western blot of concentrated HIV-1 virus
particles from culture supernatants expressing wild type or W252A RT HIV-1, detecting with anti-HIV-1 (left, human serum, NIH AIDS reagent) or anti-RT
antibodies (right). (D) The RT activities of wild type andW252A RTmutated viruses were measured using a standard RT colorimetric assay and normalized
to CA levels in each sample. (E) Jurkat cells were infected with wild type or W252A RTmutant virus using equivalent amount of CA (500 ng CA/107 cells) or
(F) equivalent amount of RT (5 ng of RT/107 cells). Virus replication was monitored by using an ELISA to measure CA in the culture supernatant at 0, 3, 7 and
14 days post-infection. The mean values and standard deviations from an experiment performed in triplicate are shown. The experiment was repeated twice
with similar results.
doi:10.1371/journal.ppat.1005289.g004
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TheW252A RTmutation significantly reduced the association of RT with
eEF1A in infected cells
Proximity ligation assays (PLA) were performed to examine the association of RT with eEF1A
in infected cells. Previously we used PLA to show an association of HIV-1 RT with eEF1A in
infected cells [9]. Similar experiments were performed here using equivalent amounts of wild
type or W252A virus, normalized to CA, to infect TZM-bl cells. The cells were fixed at 4 h
post-infection and mouse anti-RT and rabbit anti-eEF1A antibodies were used to target RT
and eEF1A, respectively, which were detected using oligonucleotide-conjugated secondary
antibodies. Heat-inactivated viruses that are defective for entry into cells were used to monitor
non-specific foci, due to low levels of non-specific antibody staining. The number of foci was
significantly reduced in cells infected by W252A RT virus compared with wild type virus (p
<0.05; Fig 5A), indicating a reduced association of W252A RT with eEF1A. The degree of cell
entry of each virus was similar, as indicated by similar levels of viral genomic RNA in cells
post-infection (Fig 5B). The PLA data correlate to decreased association of W252A RT with
eEF1A as observed in the co-IP assays (Fig 2G) and provide further evidence that a W252A
mutation in RT impairs its interaction with eEF1A.
The eEF1A inhibitor, didemnin B (Did B) inhibits HIV-1 reverse
transcription
Did B is a marine natural product depsipeptide with antiviral and antitumor properties that
can inhibit protein synthesis [24,25]. A proposed mechanism of action involves Did B irrevers-
ibly binding to a pocket in eEF1A domain 2, resulting in a conformational change that inhibits
interaction of eEF1A with the nucleotide exchange factors eEF1B and eEF2 [25–27]. We
hypothesized that binding of Did B to eEF1A may also inhibit reverse transcription via the RT-
eEF1A interaction. To compare the effect of Did B, another protein synthesis inhibitor, cyclo-
heximide (CHX), which blocks eEF2-mediated tRNA translocation by binding to the E site of
Table 3. Analysis of reverse transcription by wild type or RT-W252Amutant virus in Jurkat cells.
WT1,2,3,4 W252A1,2,3,4 p value5 WT + NVP6,4
Infection using equivalent amount of CA8 early DNA copy number 15,212 ± 3,226 11,350 ± 3,110  0.05 8,393 ±3,785
late DNA copy number 3,244 ± 696 1,332 ± 216 < 0.05 1,912 ± 598
late/early DNA % 21.3 ± 0.2 11.7 ± 0.6 22.7 ± .06
Infection using equivalent amount of RT9 early DNA copy number 9,780 ± 1,433 16,440 ± 3,745 NT7
late DNA copy number 2,207 ± 336 2,152 ± 544 NT7
late/early DNA % 22.6 ± 0.3 13.1 ± 0.4 NT7
1. The infection experiments were repeated at least three times and the mean copy numbers of DNA measured and standard deviations are shown;
2. HIV-1NL4.3;
3. HIV-1NL4.3-RT-W252A;
4. Heat inactivated virus samples measured less than 100 copies (subtracted);
5. The data sets analyzed were considered to be normal with an α value of > 0.05 standard deviations. P values from Welch’s two-tailed t test are shown,
comparing experimental and control samples as indicated;
6. Nevirapine (NVP) was added at 40 nM which is the reported IC50 in cell culture;
7. NT = Not Tested;
8. CA measured by ELISA;
9. RT measured by in vitro RT assay.
doi:10.1371/journal.ppat.1005289.t003
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the 60S ribosome [28], was used so possible effects on early HIV-1 replication could be dis-
criminated from inhibition of translation.
Firstly, the effects of Did B and CHX on protein translation were measured in Jurkat cells.
Jurkat cells were transfected with pCMV-Glu2 expressing secretable Gaussia luciferase and the
culture medium was replaced 24 h post-transfection with media containing increasing subna-
nomolar concentrations of Did B and CHX (0.032 to 0.8 nM). At 8 h and 24 h post-treatment,
Did B did not reduce levels of Gaussia luciferase in culture supernatant, while CHX modestly
decreased levels when used at 0.8 nM (p< 0.05) compared to a DMSO control (Figs 6A and
S8A), indicating that CHX had a greater negative effect on cellular translation. Cell prolifera-
tion was reduced using 0.8 nM of Did B, however a greater reduction of cell proliferation was
detected at all concentrations of CHX used (S8B Fig). The data indicate that CHX is signifi-
cantly more cytotoxic than Did B when used at 0.8 nM.
The effect of Did B and CHX on HIV-1 reverse transcription was then assessed. Jurkat cells
were treated with equivalent concentrations of Did B or CHX for 2 h prior to infection. In the
continued presence of the compounds, cells were infected with HIV-1 for 2 h at 4°C, then at
37°C for 4 h, after which the cytoplasmic nucleic acids were extracted and the levels of HIV-1
DNA in the samples were measured by qPCR. The results show that Did B strongly inhibited
reverse transcription, especially at 0.8 nM, where DNA synthesis was reduced compared to
mock (DMSO) treated cells (Fig 6B and 6C). CHX had a negligible effect on reverse transcrip-
tion at the same concentration. Most noteworthy was a change in reverse transcription effi-
ciency, as indicated by the amount of second strand DNA synthesis relative to the amount of
sssDNA produced. The maximum reverse transcription efficiency was ~24% in DMSO treated
cells, whereas reverse transcription efficiency in cells incubated in the presence of 0.8 nM Did
B was reduced ~ 3-fold (Fig 6D). At a concentration of 0.16 nM, Did B had no detectable
Fig 5. AW252A RTmutation reduces the association of RT with eEF1A in cells. Proximity ligation assays (PLA) were performed in TZM-bl cells infected
with equivalent amounts of virus normalized to CA. Foci indicating association of RT with eEF1A were detected by fluorescence microscopy of cells infected
with wild type or W252A RTmutant virus (bottom left panel), or with the same viruses that were heat-inactivated prior to infection. (A) Foci from PLA positive
cells in 20 fields totaling at least 200 cells were quantified for each infection experiment. (B) Quantitative RT-PCR analysis of viral RNA in nevirapine-treated
TZM-bl cells (to block reverse transcription of viral genomic RNA) infected with wild type or W252A RT HIV-1 or their heat-inactivated controls. The
cytoplasmic RNA was extracted 2 h post-infection and measured by RT-PCR in triplicate. All values were normalized to cellular β-tubulin mRNA levels. All
columns represent a mean value and standard deviation from at least three independent experiments. A p value for the wild type andW252A RTmutant HIV-
1 outcome is shown.
doi:10.1371/journal.ppat.1005289.g005
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Fig 6. The eEF1A inhibitor didemnin B blocks HIV-1 reverse transcription. (A) Jurkat cells transfected with pCMV-Gluc 2 were treated post-transfection
with media containing didemnin B (Did B) or cycloheximide (CHX) at concentrations as indicated. The levels of secretedGaussia luciferase in the culture
supernatants were measured 8 h post-treatment. (B andC) Jurkat cells were incubated with subnanomolar concentrations of Did B and CHX as indicated
and then infected with HIV-1 at 4°C for 2 h and 37°C for 4 h. The total cytoplasmic DNA was collected and the levels of HIV-1 early (B) and late (C) reverse
transcription products were measured by qPCR. (D) Reverse transcription efficiencies were calculated as the ratio of late to early viral DNA, expressed as a
percentage. (E) The levels of HIV-1 RNA in cells treated with didemnin B (Did B) and cycloheximide (CHX). Jurkat cells were incubated with 100 nM
nevirapine and concentrations of Did B and CHX as indicated at 37°C for 2 h followed by HIV-1 infection. The HIV-1 was incubated with cells at 4°C for 2 h
and then at 37°C for 4 h. Heat inactivated virus was used as a negative control. The HIV-1 RNA was extracted from the cells and detected by RT-qPCR. A
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cytotoxicity (Figs 6A, S8A, and S8B), but still reduced reverse transcription efficiency (Fig 6D).
No significant change in reverse transcription efficiency was observed in cells treated with
CHX compared to the DMSO treated control. The levels of mitochondrial DNA, as measured
by PCR of cytochrome c oxidase subunit II (COXII), were similar in all samples (S9A Fig),
indicating that equivalent amounts of samples were assayed. Furthermore, we excluded any
inhibition of HIV-1 entry by both Did B and CHX treatments (Fig 6E) and any direct effects of
Did B and CHX on RT activity (S9B Fig). The results demonstrate Did B can inhibit early and
late HIV reverse transcription, but that the effect of Did B on late DNA synthesis is greater,
resulting in the reduction of reverse transcription efficiency. This outcome is consistent with a
role we previously described for eEF1A in supporting the stability of the reverse transcription
complex and completion of the reverse transcription process [9].
Did B induces instability of the wild type but not W252A mutant reverse
transcription complex
Did B is believed to induce conformational changes in eEF1A [26,27], and this may affect inter-
action with RT and functionality of the RT-eEF1A complex. To determine if Did B could
directly affect the eEF1A interaction with RT, cell lysate from cells expressing HIV-1
RTp51-FLAG were incubated with 1 nM Did B, or 100 nM CHX or DMSO as controls. eEF1A
was immunoprecipitated from these treated lysates using an anti-eEF1A antibody and the cap-
tured proteins were analyzed by western blot using an anti-FLAG antibody. The results show
that treatment with 1 nM Did B resulted in a small decrease in co-IP of RT (Fig 7A), but the
difference was not statistically significant (Fig 7B).
To test the effect of Did B on RTCs and reverse transcription, large scale infections of
HEK293T cells were performed using VSV-G pseudotyped wild type and W252A mutant
HIV-1. HEK293T cells were incubated with 0.8 nM Did B or DMSO carrier for 2 h. VSV-G
pseudotyped HIV-1 was incubated with cells at 4°C for 2 h to allow virus attachment to cells,
then at 37°C for 4 h. Cell lysates were made from the infected cells and fractionated by isopyc-
nography using a 20% to 70% linear sucrose gradient. The analysis shows the bottom eight
fractions that include a sucrose density of 1.33 g/ml, which corresponded to fraction 4 (F4),
that contains viral RTCs [29] (Fig 7C–7F). Viral CA and DNA were observed with a peak in F4
in agreement with previous studies [9] and indicative of RTCs (Fig 7C–7F, boxed). While peak
profiles for the wild type and mutant HIV-1 were similar (Fig 7C vs. 7D, and 7E vs. 7F), the
W252A mutant HIV-1 made less early DNA than wild type HIV-1, in agreement with previous
experiments. Did B reduced CA levels of wild type HIV-1 by 5-fold (Fig 7C, red vs. green
lines), and early DNA levels by 13-fold (Fig 7E, red vs. green lines). Did B had a greater effect
on early DNA synthesis in our previous experiments (Fig 6B). However, Did B had no dramatic
effect on the W252A mutant HIV-1 CA or viral DNA levels in any fraction (Fig 7D and 7F, red
vs. green lines). We also measured the levels of late DNA in F4 by qPCR. The results averaged
from two experiments show that the efficiency of wild type HIV-1 reverse transcription was
~21% in untreated cells and ~11% in Did B treated cells. The W252A mutant reverse transcrip-
tion efficiency was ~12–13% in either the presence or absence of 0.8 nM Did B (Table 4). Based
on these observations, we propose that Did B inhibits reverse transcription by binding to
eEF1A thereby affecting its interaction with the RTC.
direct qPCR without RT from the RNA samples was performed to monitor for DNA contamination. All columns represent a mean value and standard deviation
from at least three independent experiments. ** = p < 0.05.
doi:10.1371/journal.ppat.1005289.g006
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Fig 7. The effect of didemnin B on RT-eEF1A interaction in vitro and viral RTCs in cells. (A) Cell lysates from HEK293T cells transiently expressing HIV
RTp51-FLAG were incubated for 30 min at 37°C with concentrations of Did B, CHX or DMSO as indicated. Immunoprecipitation was performed using a rabbit
anti-eEF1A antibody and visualized by western blot using anti-FLAG (upper panel) or mouse anti-eEF1A antibodies (lower panel). The experiment was
performed three times with similar results. (B) Western blots in (A) were analyzed by densitometry. Normalized density values for RTp51 were calculated by
dividing the relative density of RTp51 in each sample lane by the relative density of the eEF1A in the same lane [45]. The columns represent the mean
normalized densities and standard deviations of three independent experiments relative to the DMSO treated value. Student’s two-tailed T test was used to
calculate statistical significance (C—F) HEK293T cells were treated with Did B at 0.8 nM or with DMSO carrier. The cells were infected with VSV-G
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Discussion
Previously we demonstrated that the eEF1 complex associates with and had functional impor-
tance for the HIV-1 RTC [9]. Here we provide evidence that eEF1A binds tightly and specifi-
cally to RT and directly regulates reverse transcription. We previously showed that two
subunits of the eEF1 complex, eEF1A and eEF1G, could interact with the RTC components RT
and IN and affect RTC stability and its ability to complete late steps of reverse transcription.
Both HIV-1 RT and IN can be co-immunoprecipitated by antibodies specific for eEF1A or
eEF1G [9]. However, co-IP experiments cannot discriminate between direct or indirect protein
interactions. Here, BLI assays were used to investigate direct binding between RT or IN with
individual components of the eEF1 complex including eEF1A, eEF1G, eEF1D and eEF1B. BLI
assays detected strong binding between eEF1A and RT, whereas weak or no binding was
observed between other eEF1 subunits and RT or IN. For unclear reasons, downregulating
eEF1G using siRNA usually resulted in reduced level of eEF1A, which may partially explain
why down regulating eEF1G also reduces reverse transcription [9]. Interestingly, eEF1A levels
are downregulated by siRNA knockdown of eEF1Bα in cells [30]. A remarkably strong KD of
3–4 nM between the RT heterodimer and eEF1A was measured under the conditions tested,
which is a stronger interaction constant than that described for eEF1A-Gag [12]. The results
indicate that interaction between eEF1A and RT actuates the previously described association
of the eEF1 complex with the RTC [9].
BLI has the ability to detect specific binding of proteins between a probe and an analyte in
complex mixtures of molecules such as a cell lysate. Given the relative abundance of eEF1A in
cells and its strong affinity for RT, it is not surprising that knockdown of eEF1A by siRNA in
cell lysates correlated with decreased levels of RT binding in BLI assays, which could be com-
pensated by adding purified eEF1A to an eEF1A-depleted cell lysate. Given the intense interest
in cellular proteins that interact with viral proteins, reports of other cellular proteins associat-
ing with RT are surprisingly rare [31–34]. To our knowledge, only a few other cellular RT bind-
ing proteins, including AKAP149 and APOBEC3G, are reported to enhance or inhibit reverse
transcription, respectively, through direct interactions with RT [35,36]. The data presented
here provide evidence that eEF1A is an important cellular RT binding protein required for
early HIV-1 replication.
psuedotyped wild type (C and E) or W252A RTmutant (D and F) HIV-1. A lysate was prepared and viral RTCs were purified by isopycnography using a 20%
to 70% linear sucrose gradient. Fractions collected from the tube bottom were assayed for (C andD, left y-axis) CA by ELISA and (E and F, left y-axis) viral
strong stop DNA by qPCR. The density of the sucrose in each fraction (C–F, right y-axis) is indicated by the blue line. The box in each graph indicates a
fraction with a density of 1.33 g/ml. The experiment was repeated twice with similar results and a representative outcome is shown.
doi:10.1371/journal.ppat.1005289.g007
Table 4. Analysis of lysates of frommock and Did B-treated cells for viral DNA in RTC fraction 4.
WT1,3 +DMSO WT1 + Did B p value4 W252A2,3 + DMSO W252A2 + Did B p value4
early DNA copy number/μl 13304 ± 4933 1124 ± 457 <0.05 6788 ± 3780 7090 ± 4462  0.05
late DNA copy number/ μl 2781 ± 856 122 ± 48 <0.05 829 ± 368 872 ± 522  0.05
late/early DNA% 21.2 ± 2.1 10.9 ± 1.02 < 0.05 12.7 ± 2.2 12.5 ± 0.6  0.05
1. VSV-G pseudotyped HIV-1NL4.3;
2. VSV-G pseudotyped HIV-1NL4. 3-RT-W252A;
3. Heat inactivated virus samples measured no detectable copies. The experiment was repeated twice with similar outcomes. Mean values and standard
deviations of combined experiments are shown;
4. P values from Welch’s two-tailed t test are shown, comparing experimental (Did B) and control samples (DMSO) as indicated.
doi:10.1371/journal.ppat.1005289.t004
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Our experiments show that the RT thumb and connection domains are required for interac-
tion with eEF1A. We observed reduced protein interactions in co-IP experiments when regions
within the thumb domain or the entire connection domain were deleted. Given the strong
binding between RT and eEF1A, multiple contacts between the two proteins are likely. The
W252A and L303A mutants, in particular, are interesting because their side-chains are buried
in the RT core and unlikely contact points between RT and eEF1A, and their individual muta-
tion to alanine imparts a localized structural change that is sufficient to disrupt RT interaction
with eEF1A. An HIV sequence database search indicates that W252 and L303 residues are
largely invariant residues demonstrating their importance in RT structure and function, and
we were unable to find other studies investigating RT with mutations in these positions. Our
analysis of the W252A RT mutant provides a proof of concept that negatively impacting the
RT-eEF1A interaction leads to reduced reverse transcription efficiency and HIV-1 replication.
Our modeling and MAPPIT experiments testing dimerization of RT subunits support the
interpretation that W252A acts by inducing a localized change in RT structure that does not
affect RT dimerization. The modeling also predicts that a T253A mutation will not affect RT
structure and RT protein containing this mutation efficiently binds to eEF1A in co-IP assays
indicating specificity for the W252 region. Further analysis of the thumb and connection
domains and their effect on RT interaction with eEF1A will be fertile ground for future
research.
Didemnin B is a depsipeptide isolated from a Caribbean tunicate that has reported antiviral,
anti-tumor, and anti-translation effects [24–26]. When comparing matched subnanomolar
concentrations of CHX and Did B, we found that CHX is a stronger translation inhibitor with
greater cytotoxic effects in Jurkat cells compared to Did B. However, only Did B reduced the
efficiency of reverse transcription, the ratio of the late to early viral DNA reverse transcription
products. Interestingly Did B strongly decreased RTC levels and reduced DNA synthesis in
cells infected with wild type HIV-1 but not with the RTW252A mutant. It suggests that eEF1A
plays a broader role in reverse transcription, a concept supported by the observation that
eEF1A is specifically packaged in HIV-1 virions [12], and can interact with the HIV-1 5’ UTR
genomic RNA as well as with RT [37]. Our experiment supports a model (Fig 8) in which Did
B irreversibly binds to eEF1A [25], associated with RT leading to instability of the RTC and
viral core supporting the RTC, thereby negatively effecting both early and late DNA synthesis
during reverse transcription. However Did B has a greater effect on late DNA synthesis com-
pared to early consistent with the observation that the RT–eEF1A complex is particularly
important for the late phase of reverse transcription, in agreement with our previous study [9].
However RTCs with a RTW252A mutant, which can interact with eEF1A but at reduced levels
compared to wild type RT (Figs 2 and 3), maintain an RTC complex capable of strong stop
DNA synthesis whereas late DNA synthesis occurs at reduced efficiency (Table 4). The con-
trasting Did B-sensitivity of HIV-1 wild type andW252A mutant RT indicates that Did B
affects reverse transcription through the RT-eEF1A interaction and not by off-target effects.
Studies of tombusvirus, a non-enveloped positive sense single-stranded RNA plant virus,
provide evidence that Did B inhibits viral replicase activity by blocking replicase formation
through binding to eEF1A [38]. The fact that eEF1A can assume a partially unstructured con-
formation [39] may underlie its ability to interact with many different viral proteins and
RNAs. While Did B strongly impaired reverse transcription, it is not a therapeutic drug due to
toxicity. However, eEF1A is targeted by other compounds without toxic effects [40,41]. Hence,
detailed knowledge of the RT-eEF1A interaction could lead to the identification of agents that
impede their interaction without detrimental effects to the cell, thereby nominating well toler-
ated, lead anti-viral candidates that target a druggable host-pathogen interaction.
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Materials and Methods
Cell lines and virus culture
HEK293T (ATCC) and TZM-bl (NIH AIDS Reagent Program) cell lines were grown in Dul-
becco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum,
penicillin (50 I.U./ml)-streptomycin (50 μg). Jurkat (Clone E6-1, ATCC) cells were grown in
RPMI 1640 supplemented with 10% fetal bovine serum, penicillin (50 I.U./ml) and streptomy-
cin (50 μg/ml). All cell lines were incubated at 37°C in 5% CO2. A stock of HIV-1NL4.3 and the
same strain with a mutated RT gene, HIV-1 NL4.3-pol-W252A, were generated by transfection
Fig 8. Did B inhibits early HIV-1 replication by targeting the RT-eEF1A interaction. Immediately following fusion of the viral and cellular membrane, the
viral core and matrix are released into the cytoplasm. Subsequently the viral core undergoes uncoating and reverse transcription. Here we propose that
eEF1A is recruited to the RTC by a direct interaction with RT that increases the efficiency of reverse transcription completion. It is unclear if virion eEF1A [12],
target cell eEF1A or both are required. HIV-1 containing a W252A RTmutant has decreased ability to interact with eEF1A. Treating cells with Did B
generates pools of eEF1A-Did B as well was RT-eEF1A-DidB complexes. The RT-eEF1A-Did B complex does not support uncoating and reverse
transcription and results in decreased RTC levels and reduced DNA synthesis. The status of other RTC protein interactions requires experimental
confirmation (as denoted by a “?”). However, a W252A RT mutant HIV-1 is unaffected by Did B because its interaction with eEF1A, or with a eEF1A - Did B
complex, is downregulated and catalyzes reverse transcription in either the presence or absence of Did B albeit at reduced efficiency.
doi:10.1371/journal.ppat.1005289.g008
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into HEK293T cells of the corresponding proviral DNA using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) according to the manufacturer's recommendations. Cell culture supernatants
were collected at 48 h post-transfection and centrifuged (200 × g, 10 min), and the supernatant
was filtered (0.45 μm) and stored in 1 ml aliquots at −80°C.
BLI assay
Full-length human proteins expressed in HEK293 cells including eEF1A1, 1B2, 1G and 1D pro-
teins having C-terminal MYC/DDK tags were purchased from OriGene (OriGene Technolo-
gies, MD, USA) and recombinant 6×His-tagged HIV-1 RT p51, RT p66, IN and Gag produced
in E. coli were gifts from Stuart LeGrice, Duane Grandgenett and Johnson Mak, respectively.
The proteins were biotinylated using EZ-Link Sulfo-NHS-Biotin following the manufacturer’s
instructions (Pierce Biotechnology, IL, USA). The biotinylated proteins were immobilized onto
streptavidin-coated biosensors (Pall ForteBio, CA, USA). A standard kinetic buffer (1 mM
phosphate, 15 mMNaCl, 0.002% Tween-20 and 0.1 mg/ml gelatine) was used in all experi-
ments unless noted. The association (ka) of the two proteins was measured by incubating
ligand biosensors (biotinylated protein) into kinetic buffer containing protein (analyte) with
1000 rpm shaking in the OctetRed system. Concentrations of analyte ranging from 90 nM to
10 nM were assayed. The dissociation (kd) was determined by moving the ligand biosensor
from kinetic buffer containing analyte to the standard kinetic buffer.
When cell lysates were used in BLI assay, the total protein concentration was adjusted to
0.5mg/ml using kinetic buffer and the biosensors immobilized with RT51/66. In add back
experiment, the purified eEF1A protein was added into siRNA treated cell lysate to the final
concentration of 45 nM, or the same amount of BSA was added other cell lysates.
siRNA treatment
siRNA (Sigma-Aldrich) targeting eEF1A (siRNA ID: SASI_Hs02_00331772 and 00331773) and
control siRNA (SIC001) were applied to HEK293T cells by large-scale reverse transfection using
Lipofectamine RNAiMAX according to the manufacturer’s instructions (Invitrogen). The cell
lysates were prepared using a Dounce homogenizer in S100 buffer at 48 h of post-transfection
and cleared by centrifugation 16,000g for 30 min at 4°C as previously described [9].
Plasmids
For expression of HIV-1 RT p51, p66, IN and Gag separately in cells, the coding DNA
sequences were amplified from pHGPsyn construct [42], which contains a codon optimized
Gag-Pol sequence that was inserted into pDONR vector using Gateway system (Invitrogen,
USA) by a BP recombination reaction. The inserts were then transferred into destination mam-
malian expression vectors that contain FLAG or V5 and 6×His tags by LR recombination reac-
tions. Internal deletions and mutations of RT in the destination vector were made by inverse
PCR. Inverse PCR is also used to make RT mutated proviral plasmid using pGCHIV-1-NL4-3
construct as a template [43]. The secreted Gaussia luciferase expression construct, pCMV-Gluc
2 was purchased from NEB (NEB, USA). The sequences of the primers used are available on
request.
Virus infection, DNA extraction and analysis of reverse transcription
DNA synthesis
HIV-1NL4.3 virus stock was treated with DNase I at 37°C for 30 min to remove any DNA con-
tamination prior to adding to cells. Jurkat cells were incubated with HIV-1NL4.3 virus in
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presence of 8 μg/ml polybrene at 4°C for 2 h and then 37°C for 4 h. The cells were then washed
three times with 0.1 mM EDTA PBS, and lysed using Glo Lysis Buffer (Promega). The lysate
was centrifuged (20,000 x g, 10 min). The supernatant was extracted once with an equal volume
of phenol:chloroform:isoamyl alcohol (25:24:1) and once with chloroform. The extracts were
ethanol precipitated, washed with 70% (vol/vol) ethanol, and resuspended in 0.1 mM EDTA.
The early and late reverse transcription products were analyzed by quantitative PCR as else-
where described [6].
Co-immunoprecipitation (Co-IP) and protein analysis
Co-IP was performed as elsewhere described [9]. Briefly, cells expressing various wild type or
mutant HIV-1 proteins having V5 or FLAG epitope tags were lysed in S100 buffer (10 mM
Tris, pH 7.4, 1.5 mMMgCl2, 10 mM KCl, 1× complete protease inhibitor cocktail [Roche], and
0.5 mM β-mercaptoethanol) using a Dounce homogenizer. The lysate was cleared by centrifu-
gation in a microfuge (4°C, 20,000 x g, 10 min). The supernatant was incubated with anti-
eEF1A rabbit antibody or rabbit IgG coupled Dynabeads Protein G (Invitrogen, USA) for 2 h
at 4°C. The immunoprecipitate was washed three times with S100 buffer plus 0.1% Triton-
x100 followed by western blot analysis using anti-FLAG, anti-V5 antibodies or a mouse anti-
eEF1A antibody (Santa Cruz) as indicated. Where indicated western blots were probed with
anti-HIV-1 immunoglobulin (HIV-IG, obtained through the NIH AIDS Reagent Program,
Division of AIDS, NIAID, NIH: Catalog #3957, HIV-IG from NABI and NHLBI) and HIV-1
RT antibody (39/4.12.2) (Santa Cruz). The Agilent 2100 system and Protein 230 kits were used
to evaluate protein lysate used in the study according to the manufacturer’s instructions. Some
western blots were analyzed using ImageJ software [44] following published procedures [45].
Purification of recombinant RT wild type and mutants
The plasmids containing wild type or mutant RT p66 in pDEST 40 vector (Invitrogen, USA)
were transformed into BL21 AI bacterial cells (Invitrogen, USA). The cells were cultured to the
density of OD600 ~0.4 and the protein expression was induced by the final concentration of
1mM IPTG and 0.2% L-arabinose (Sigma, USA). The protein purification was carried out
using the HisLink protein purification system according the product protocol (Promega, USA).
The purified proteins were dialyzed using MINI dialysis unit (Thermo Scientific, USA) in PBS
and examined by SDS PAGE and Coomassie blue staining.
Proximity ligation assay (PLA)
PLA assay was performed as elsewhere described [9]. Briefly, TZM-bl cells were incubated with
HIV-1NL4.3 or HIV-1NL4.3-pol-W252A (equivalent to 500 ng CA) at 4°C for 2 h to allow virus
attachment. Heat-inactivated virus (85°C, 15 min) were used as a negative control. The cells
were then incubated at 37°C for 4 h to permit virus fusion with the cells and reverse transcrip-
tion. Cells were fixed using 4% paraformaldehye followed by permeabilization using acetone.
Duolink proximity ligation assays were performed using a mouse monoclonal antibody to
detect HIV-1 RT in conjunction with a rabbit antibody to eEF1A (Santa Cruz). Otherwise PLA
reactions were performed according to the manufacturer’s instructions (Sigma-Aldrich). DAPI
stain was used to visualize the nuclei. Cells were visualized using a DeltaVision Core imaging
system. Maximum-intensity projections of deconvolved images were analyzed using Duolink
Image Tool software. More than 200 cells from at least 20 fields were analyzed for each
experiment.
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Structure-based analysis of the HIV-RT p66/p51 mutations
A BLAST search [46] was undertaken for Gag-Pol reverse transcriptase sequence 588–1147
(i.e. the p66 sequence, incorporating p51) against the Protein Data Bank (PDID B) [47] using
an E-value cut-off 10−20. A total of 406 equivalent or related structures/domains were retrieved
and the X-ray structure with the highest resolution among them (PDID B ID: 4G1Q) [15] that
matched the lengths of the p66/p51 sequence was used for further analysis.
The empirical forcefield FoldX [16,48] under the YASARA [49,50] molecular visualization
program was used to estimate the free energy difference (stability change) upon mutagenesis
from wild-type. Mutagenesis of W252A and T253A was undertaken in silico with the individ-
ual p51 and p66 subunits, and the p51/p66 heterodimer, independently. The ‘RepairPDB’
option followed by the ‘Mutate residue’ option of FoldX was used to calculate the stability
change with default parameters (Number of runs: 3; pH: 7; Temperature: 298 K; Ionic strength:
0.05 M; VdW design: 2). All resulting energies are expressed in kcal/mol. The result is the delta
Gibbs free energy (ΔΔG) of mutation expressed in kcal/mol; average of 3 calculation runs is
reported. The error margin of FoldX is ~0.5 kcal/mol, so changes in that range are considered
insignificant. The prediction decision on whether the mutation stabilises or destabilises the
structure is based upon [16,48] where; no effect on structural stability: ΔΔG is< 1.6 kcal/mol,
and severely reduced structural stability: ΔΔG is> 1.6 kcal/mol.
Inter and intra-protein residue interactions were determined using the Protein Interactions
Calculator (PIC) [51]. ASAView [52] was used to determine residue solvent accessibility.
PyMol (http://www.pymol.org) was used for visualization and analysis.
HIV-1 CA ELISA and in vitro RT assay
HIV-1 CA in the culture supernatant was measured by using a RETROtek HIV-1 CAp24 anti-
gen ELISA (Zeptometrix, USA), according to the manufacturer's instructions. For RT analysis,
after the addition of detergent to virions, an RT assay (Roche) was used to measure RT activity
released from virions using a poly(A):oligo(dT)15 template following the manufacturer's
instructions.
Translation inhibitor experiments
Did B was kindly provided by the Natural Products Branch, NCI (NSC 325319, Bethesda, MD,
USA), and CHX was purchased from Sigma Aldrich. Both chemicals were dissolved in DMSO
for stock. To monitor translation of proteins, Jurkat cells were transfected with pCMV-Gluc 2
plasmid and seeded in 24-well plate. At 5 h post-transfection, serially diluted stocks of Did B
and CHX were added at concentrations of 0.032, 0.16 and 0.8 nM. The luciferase activity in cul-
ture supernatant was measured after 8 h and 24 h of treatment using Biolux Gaussia luciferase
Flex Assay kit (NEB). Cell proliferation was monitored using CellTiter 96 AQueous One Solu-
tion Cell Proliferation assay (Promega), as instructed by the manufacturer.
HIV-1 entry assay
TZM-b1 or Jurkat cells were treated with nevirapine at 1 μM/ml for 2 h incubated at 37°C and
with HIV-1 (wild type or mutant) for 2 h at 4°C to facilitate virus attachment and then at 37°C
for 2 h to initiate fusion and entry. Cellular nucleic acids were collected using Trizol reagent
(Life Technologies) and the RNA fraction was column purified using a Direct-zol mini-prep
kit (Zymo Research) and treated on the column with DNase I prior to elution. The purified
RNAs were used in RT-PCR reactions both with and without SuperScript III reverse transcrip-
tase (Life Technologies) using random hexamer oligonucleotides for the first strand DNA
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synthesis. Second strand DNA and PCR was performed using oligonucleotides specific for full
length viral mRNA as previously described [4]. A no template control was included in each
experiment.
Mammalian protein-protein interaction trap (MAPPIT)
The interaction of HIV RT p51 and p66 subunits was performed using MAPPIT system as pre-
viously described with modification [19,20]. Briefly, RTp51 and its mutants were inserted into
the bait vector using BamH I and Not I cut site. RTp66 and its mutant were inserted into the
prey vector using EcoR I and Xho I cut site. 293T cells were grown in 12 well-plate and trans-
fected using Xtremegene (Roche) with 500 ng bait plasmid (either wild type or mutant HIV-1
RTp51), 500 ng prey plasmid (either wild type or mutant HIV-1 p66), 100 ng of reporter plas-
mid (pXP2d2-rPAP1-luciferase) and 100 ng of a plasmid (pCMV-GLuc2) to monitor transfec-
tion efficiency. A final concentration 100ng/ml of leptin (recombinant mouse leptin, R&D
systems, USA) was added to the cells at 24 h post-transfection. The culture supernatant and
cells were collected after additional 24 h. Gaussia luciferase was measured from culture super-
natant to normalize transfection efficiencies and the firefly luciferase was measured from cell
lysate to determine the RTp51 and RTp66 interaction.
RTC purification and sucrose gradient
Purification of HIV-1 RTCs was carried out as previously described [9], with minor modifica-
tions. HEK293T were treated with 0.8 nM Did B or same volume of DMSO for 2 h at 37°C and
then incubated with same amount (equivalent to Cap24), DNAseI treated VSV-G pseudotyped
HIV-1NL4.3 or HIV-1 NL4.3-pol-W252A stock for 2 h at 4°C with polybrene (80 μg/mL) and
then incubated at 37°C for 4 h. Heat-inactivated virus were used as a negative control. The
RTCs were prepared as previous described [53] and placed on top of a linear sucrose gradient
(20–70%, wt/wt) and subjected to centrifugation at 145,000 × g for 18 h at 4°C. Eight fractions
were collected from the tube bottom and assayed by qPCR for HIV-1 negative strand strong
stop DNA as previously described [9] and by ELISA for HIV-1 CA (Zeptometrix Corporation).
Statistical analysis
Statistical analyses were performed using the Student’s t-test from at least three independent
experiments or measurements. Statistical significance was set at p< 0.05.
Supporting Information
S1 Fig. Sensorgram of association and dissociation of eEF1A1, eEF1B, eEF1D and eEF1G
with HIV RT. Biotinylated (A) eEF1A1, (B) eEF1B, (C) eEF1D and (D) eEF1G were immobi-
lized on biosensors. The association and dissociation with various concentrations of HIV
RTp66/p51 were measured respectively on the OctetRed system. Data are representative of
three independent experiments.
(PPTX)
S2 Fig. Sensorgram of association and dissociation of eEF1A1 with subunits of RT, the RT
heterodimer and Gag. Biotinylated eEF1A1 was immobilized on biosensors. The association
and dissociation of eEF1A with various concentrations of HIV RT subunit (A) p51, (B) p66,
(C) p66/p51 heterodimer and (D) Gag were measured with the OctetRed system. Data are rep-
resentative of three independent experiments.
(PPTX)
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S3 Fig. eEF1A can co-immunoprecipitate with RT. FLAG-tagged RT51 was expressed in
HEK293T cells by plasmid transfection. Cell lysates were prepared 24 h post-transfection and
subjected to immunoprecipitation using an anti-FLAG antibody. The detection of eEF1A (A),
eIF3A (B) and RT (C) in cell lysate (left column) and the co-immunoprecipitated eEF1A (right
column, top panel) were detected by western blot. A lysate from mock-transfected cells was
used as a control.
(PPTX)
S4 Fig. Ribbon diagrams representing the highest resolved crystal structure of the p66/p51
heterodimer (PDB B ID: 4G1Q). The W252 is located in the loop region just before the first
alpha-helix of the thumb domain and is shown in sphere representation (red) within each sub-
unit.
(PPTX)
S5 Fig. Association of eEF1A with purified RT66 and mutants. Purified wild type RT p66
and mutant RTW252A, L303A mutants were analyzed using SDS-PAGE followed by Coomas-
sie blue staining (A). In BLI assay, purified eEF1A was immobilized on the biosensors and
incubated in solutions containing purified RT. The association maximums of 90 nM of wild
type RT and mutants was compared (B). The data is presented as a mean value ± standard
deviation from 3 independent experiments. p<0.05.
(PPTX)
S6 Fig. Mammalian protein-protein interaction trap (MAPPIT) is a cytokine receptor-
based mammalian two hybrid method for analysis of protein-protein interactions. A leptin
receptor deficient for STAT3 recruitment (red) is C-terminally to a bait protein (orange), in this
case either RTp66 or RTp51. A flexible spacer (green) separates the fused proteins. A prey protein
(purple) is N-terminally fused to a gp130 chain with four functional STAT3 recruitment sites. In
the presence of ligand, interaction between the bait and prey leads to complementation of
STAT3 signaling and activation of a reporter luciferase gene expressed by the rPAP1 promoter.
(PPTX)
S7 Fig. The RT mutations W252A and T253A do not affect RT dimerization. The dimeriza-
tion of RTp66 and RTp51 was investigated by MAPPIT. The pXP2d2-rPAP1-luciferase
reporter plasmid was co-transfected with combinations of wild type or mutant, W252A (252A)
and T253A (253A), RTp51 bait and RTp66 prey expression plasmids into HEK293T cells as
shown. A bait construct having the myeloid differentiation primary response protein 88
(hMvD88) and a prey construct having SV40 large T antigen (SVT) were used as negative con-
trols. Leptin (100 nM) was added to the cells at 20 h post-transfection and the cellular lysate
was prepared 24 h later and used in luciferase assays. The data is presented as a mean
value ± standard deviation from at least 3 independent experiments.
(PPTX)
S8 Fig. Translation inhibition and cytotoxicity of didemnin B (Did B) and cycloheximide
(CHX) in Jurkat cells. (A) The plasmid pCMV-Gluc2 was transfected into Jurkat cells for
luciferase expression and Did B or CHX were added at concentrations as indicated. The levels
of luciferase in culture supernatant were measured 24 h after treatment. (B) Jurkat cells were
incubated with concentrations of Did B and CHX as indicated for 24 h at 37°C and then incu-
bated with CellTiter 96 AQueous One Solution Cell Proliferation solution for 2 h at 37°C. The
absorbance was measured at 490nm in a 96-well plate reader. The data is presented as a mean
value ± standard deviation from at least 3 independent experiments. p< 0.05
(PPTX)
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S9 Fig. Effect of Did B and CHX on cytoplasmic nucleic acid sample COXII levels and in
vitro RT activity. (A) The copy number of COXII in DNA samples extracted from Did B and
CHX treated cells. Jurkat cells were incubated with various concentrations of Did B and CHX
followed by HIV-1 infection. The cytoplasmic nucleic acids were extracted from cells and
COXII levels were measured by qPCR. (B) In vitro RT activity in the presence of Did B, CHX
and nevirapine (NVP). RT (0.5 ng) was incubated with concentrations of Did B, CHX and
NVP using the Roche Reverse Transcriptase Assay (colorimetric). The data is presented as a
mean value ± standard deviation from at least 3 independent experiments.
(PPTX)
Acknowledgments
We thank Stuart LeGrice for kindly providing the recombinant HIV-1 RT protein, Duane
Grandgenett for kindly providing the recombinant HIV-1 IN protein, Johnson Mak for kindly
providing the recombinant Gag protein and Jan Tavernier for providing the MAPPIT plas-
mids. The following reagent was obtained through the NIH AIDS Reagent Program, Division
of AIDS, NIAID, NIH: TZM-bl from Dr. John C. Kappes, Dr. XiaoyunWu and Tranzyme Inc.
Author Contributions
Conceived and designed the experiments: DH DL TW. Performed the experiments: DL TW
DJR FQ RW. Analyzed the data: DCS DH CMA KS. Contributed reagents/materials/analysis
tools: HJ HS MHL. Wrote the paper: DL DJR TWDCS HS KS CMA DH.
References
1. HuWS, Hughes SH (2012) HIV-1 reverse transcription. Cold Spring Harb Perspect Med 2:a006882.
doi: 10.1101/cshperspect.a006882 PMID: 23028129
2. Harrich D, Ulich C, Garcia-Martinez LF, Gaynor RB (1997) Tat is required for efficient HIV-1 reverse
transcription. EMBO J 16: 1224–1235. PMID: 9135139
3. Apolloni A, Meredith LW, Suhrbier A, Kiernan R, Harrich D (2007) The HIV-1 Tat protein stimulates
reverse transcription in vitro. Curr HIV Res 5: 473–483. PMID: 17896967
4. Meredith LW, Sivakumaran H, Major L, Suhrbier A, Harrich D (2009) Potent inhibition of HIV-1 replica-
tion by a Tat mutant. PLoS One 4: e7769. doi: 10.1371/journal.pone.0007769 PMID: 19901984
5. Kameoka M, Rong L, Gotte M, Liang C, Russell RS, et al. (2001) Role for human immunodeficiency
virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral
replication. J Virol 75: 2675–2683. PMID: 11222691
6. Warrilow D, Meredith L, Davis A, Burrell C, Li P, et al. (2008) Cell factors stimulate human immunodefi-
ciency virus type 1 reverse transcription in vitro. J Virol 82: 1425–1437. PMID: 18045931
7. Narayan S, Young JA (2004) Reconstitution of retroviral fusion and uncoating in a cell-free system.
Proc Natl Acad Sci U S A 101: 7721–7726. PMID: 15128947
8. Hooker CW, Harrich D (2003) The first strand transfer reaction of HIV-1 reverse transcription is more
efficient in infected cells than in cell-free natural endogenous reverse transcription reactions. J Clin
Virol 26: 229–238. PMID: 12600654
9. Warren K, Wei T, Li D, Qin F, Warrilow D, et al. (2012) Eukaryotic elongation factor 1 complex subunits
are critical HIV-1 reverse transcription cofactors. Proc Natl Acad Sci U S A 109: 9587–9592. doi: 10.
1073/pnas.1204673109 PMID: 22628567
10. Sasikumar AN, PerezWB, Kinzy TG (2012) The many roles of the eukaryotic elongation factor 1 com-
plex. Wiley Interdiscip Rev RNA 3: 543–555. doi: 10.1002/wrna.1118 PMID: 22555874
11. Warrilow D, Warren K, Harrich D (2010) Strand transfer and elongation of HIV-1 reverse transcription is
facilitated by cell factors in vitro. PLoS One 5: e13229. doi: 10.1371/journal.pone.0013229 PMID:
20949087
12. Cimarelli A, Luban J (1999) Translation elongation factor 1-alpha interacts specifically with the human
immunodeficiency virus type 1 Gag polyprotein. J Virol 73: 5388–5401. PMID: 10364286
The Cell Factor eEF1A Is an Important HIV RT Binding Protein
PLOS Pathogens | DOI:10.1371/journal.ppat.1005289 December 1, 2015 25 / 27
13. Herschhorn A, Oz-Gleenberg I, Hizi A (2008) Quantitative analysis of the interactions between HIV-1
integrase and retroviral reverse transcriptases. Biochem J 412: 163–170. doi: 10.1042/BJ20071279
PMID: 18260826
14. Fang Y (2009) Guest editor's introduction: Label-free optical biosensors to cell biology and drug discov-
ery. Introduction. J Recept Signal Transduct Res 29: 127. doi: 10.1080/10799890903079869 PMID:
19640218
15. Kuroda DG, Bauman JD, Challa JR, Patel D, Troxler T, et al. (2013) Snapshot of the equilibrium dynam-
ics of a drug bound to HIV-1 reverse transcriptase. Nat Chem 5: 174–181. doi: 10.1038/nchem.1559
PMID: 23422558
16. Guerois R, Nielsen JE, Serrano L (2002) Predicting changes in the stability of proteins and protein com-
plexes: a study of more than 1000 mutations. J Mol Biol 320: 369–387. PMID: 12079393
17. Tokuriki N, Stricher F, Schymkowitz J, Serrano L, Tawfik DS (2007) The stability effects of protein muta-
tions appear to be universally distributed. J Mol Biol 369: 1318–1332. PMID: 17482644
18. Rakoczy EP, Kiel C, McKeone R, Stricher F, Serrano L (2011) Analysis of disease-linked rhodopsin
mutations based on structure, function, and protein stability calculations. J Mol Biol 405: 584–606. doi:
10.1016/j.jmb.2010.11.003 PMID: 21094163
19. Eyckerman S, Verhee A, der Heyden JV, Lemmens I, Ostade XV, et al. (2001) Design and application
of a cytokine-receptor-based interaction trap. Nat Cell Biol 3: 1114–1119. PMID: 11781573
20. Pattyn E, Lavens D, Van der Heyden J, Verhee A, Lievens S, et al. (2008) MAPPIT (MAmmalian Pro-
tein-Protein Interaction Trap) as a tool to study HIV reverse transcriptase dimerization in intact human
cells. J Virol Methods 153: 7–15. doi: 10.1016/j.jviromet.2008.06.021 PMID: 18640157
21. Ghosh M, Jacques PS, Rodgers DW, Ottman M, Darlix JL, et al. (1996) Alterations to the primer grip of
p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization. Biochemistry
35: 8553–8562. PMID: 8679616
22. Tachedjian G, Aronson HE, Goff SP (2000) Analysis of mutations and suppressors affecting interac-
tions between the subunits of the HIV type 1 reverse transcriptase. Proc Natl Acad Sci U S A 97: 6334–
6339. PMID: 10841542
23. Sarafianos SG, Marchand B, Das K, Himmel DM, Parniak MA, et al. (2009) Structure and function of
HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J Mol Biol 385:
693–713. doi: 10.1016/j.jmb.2008.10.071 PMID: 19022262
24. Rinehart KL Jr., Gloer JB, Hughes RG Jr., Renis HE, McGovren JP, et al. (1981) Didemnins: antiviral
and antitumor depsipeptides from a caribbean tunicate. Science 212: 933–935. PMID: 7233187
25. Li LH, Timmins LG, Wallace TL, Krueger WC, Prairie MD, et al. (1984) Mechanism of action of didemnin
B, a depsipeptide from the sea. Cancer Lett 23: 279–288. PMID: 6744252
26. SirDeshpande BV, Toogood PL (1995) Mechanism of protein synthesis inhibition by didemnin B in
vitro. Biochemistry 34: 9177–9184. PMID: 7619818
27. Marco E, Martin-Santamaria S, Cuevas C, Gago F (2004) Structural basis for the binding of didemnins
to human elongation factor eEF1A and rationale for the potent antitumor activity of these marine natural
products. J Med Chem 47: 4439–4452. PMID: 15317456
28. Schneider-Poetsch T, Ju J, Eyler DE, Dang Y, Bhat S, et al. (2010) Inhibition of eukaryotic translation
elongation by cycloheximide and lactimidomycin. Nat Chem Biol 6: 209–217. PMID: 20118940
29. Fassati A, Goff SP (2001) Characterization of intracellular reverse transcription complexes of human
immunodeficiency virus type 1. J Virol 75: 3626–3635. PMID: 11264352
30. Cao Y, Portela M, Janikiewicz J, Doig J, Abbott CM (2014) Characterisation of translation elongation
factor eEF1B subunit expression in mammalian cells and tissues and co-localisation with eEF1A2.
PLoS One 9: e114117. doi: 10.1371/journal.pone.0114117 PMID: 25436608
31. Warren K, Warrilow D, Meredith L, Harrich D (2009) Reverse Transcriptase and Cellular Factors: Regu-
lators of HIV-1 Reverse Transcription. Viruses 1: 873–894. doi: 10.3390/v1030873 PMID: 21994574
32. Warrilow D, Harrich D (2007) HIV-1 replication from after cell entry to the nuclear periphery. Curr HIV
Res 5: 293–299. PMID: 17504171
33. Lemay J, Maidou-Peindara P, Bader T, Ennifar E, Rain JC, et al. (2008) HuR interacts with human
immunodeficiency virus type 1 reverse transcriptase, and modulates reverse transcription in infected
cells. Retrovirology 5: 47. doi: 10.1186/1742-4690-5-47 PMID: 18544151
34. Ahn J, Byeon IJ, Dharmasena S, Huber K, Concel J, et al. (2010) The RNA binding protein HuR does
not interact directly with HIV-1 reverse transcriptase and does not affect reverse transcription in vitro.
Retrovirology 7: 40. doi: 10.1186/1742-4690-7-40 PMID: 20459669
The Cell Factor eEF1A Is an Important HIV RT Binding Protein
PLOS Pathogens | DOI:10.1371/journal.ppat.1005289 December 1, 2015 26 / 27
35. Lemay J, Maidou-Peindara P, Cancio R, Ennifar E, Coadou G, et al. (2008) AKAP149 binds to HIV-1
reverse transcriptase and is involved in the reverse transcription. J Mol Biol 383: 783–796. doi: 10.
1016/j.jmb.2008.08.055 PMID: 18786546
36. Wang X, Ao Z, Chen L, Kobinger G, Peng J, et al. (2012) The cellular antiviral protein APOBEC3G inter-
acts with HIV-1 reverse transcriptase and inhibits its function during viral replication. J Virol 86: 3777–
3786. doi: 10.1128/JVI.06594-11 PMID: 22301159
37. Li D, Wei T, Jin H, Rose A, Wang R, et al. (2015) Binding of the eukaryotic translation elongation factor
1A with the 5'UTR of HIV-1 genomic RNA is important for reverse transcription. Virol J 12: 118. doi: 10.
1186/s12985-015-0337-x PMID: 26242867
38. Li Z, Pogany J, Tupman S, Esposito AM, Kinzy TG, et al. (2010) Translation elongation factor 1A facili-
tates the assembly of the tombusvirus replicase and stimulates minus-strand synthesis. PLoS Pathog
6: e1001175. doi: 10.1371/journal.ppat.1001175 PMID: 21079685
39. Budkevich TV, Timchenko AA, Tiktopulo EI, Negrutskii BS, Shalak VF, et al. (2002) Extended confor-
mation of mammalian translation elongation factor 1A in solution. Biochemistry 41: 15342–15349.
PMID: 12484773
40. Tash JS, Attardi B, Hild SA, Chakrasali R, Jakkaraj SR, et al. (2008) A novel potent indazole carboxylic
acid derivative blocks spermatogenesis and is contraceptive in rats after a single oral dose. Biol Reprod
78: 1127–1138. doi: 10.1095/biolreprod.106.057810 PMID: 18218612
41. Tash JS, Chakrasali R, Jakkaraj SR, Hughes J, Smith SK, et al. (2008) Gamendazole, an orally active
indazole carboxylic acid male contraceptive agent, targets HSP90AB1 (HSP90BETA) and EEF1A1
(eEF1A), and stimulates Il1a transcription in rat Sertoli cells. Biol Reprod 78: 1139–1152. doi: 10.1095/
biolreprod.107.062679 PMID: 18218611
42. Wagner R, Graf M, Bieler K, Wolf H, Grunwald T, et al. (2000) Rev-independent expression of synthetic
gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implica-
tions for the safety of lentiviral vectors. Hum Gene Ther 11: 2403–2413. PMID: 11096444
43. Lin MH, Sivakumaran H, Apolloni A, Wei T, Jans DA, et al. (2012) Nullbasic, a Potent Anti-HIV Tat
Mutant, Induces CRM1-Dependent Disruption of HIV Rev Trafficking. PLoS One 7: e51466. doi: 10.
1371/journal.pone.0051466 PMID: 23251541
44. Schneider CA, RasbandWS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat
Methods 9: 671–675. PMID: 22930834
45. Gassmann M, Grenacher B, Rohde B, Vogel J (2009) Quantifying Western blots: pitfalls of densitome-
try. Electrophoresis 30: 1845–1855. doi: 10.1002/elps.200800720 PMID: 19517440
46. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, et al. (1997) Gapped BLAST and PSI-
BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389–3402.
PMID: 9254694
47. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic
Acids Res 28: 235–242. PMID: 10592235
48. Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, et al. (2005) The FoldX web server: an online
force field. Nucleic Acids Res 33: W382–388. PMID: 15980494
49. Van Durme J, Delgado J, Stricher F, Serrano L, Schymkowitz J, et al. (2011) A graphical interface for
the FoldX forcefield. Bioinformatics 27: 1711–1712. doi: 10.1093/bioinformatics/btr254 PMID:
21505037
50. Krieger E, Koraimann G, Vriend G (2002) Increasing the precision of comparative models with
YASARA NOVA—a self-parameterizing force field. Proteins 47: 393–402. PMID: 11948792
51. Tina KG, Bhadra R, Srinivasan N (2007) PIC: Protein Interactions Calculator. Nucleic Acids Res 35:
W473–476. PMID: 17584791
52. Ahmad S, Gromiha M, Fawareh H, Sarai A (2004) ASAView: database and tool for solvent accessibility
representation in proteins. BMC Bioinformatics 5: 51. PMID: 15119964
53. Fassati A (2009) Methods of preparation and analysis of intracellular reverse transcription complexes.
Methods Mol Biol 485: 107–119. doi: 10.1007/978-1-59745-170-3_8 PMID: 19020821
The Cell Factor eEF1A Is an Important HIV RT Binding Protein
PLOS Pathogens | DOI:10.1371/journal.ppat.1005289 December 1, 2015 27 / 27
